S-nitrosylation of viral proteins: Molecular bases for antiviral effect of nitric oxide

IUBMB Life

Volumn 48, Issue 1, 1999, Pages 25-31

  Colasanti, Marco ^a   Persichini, Tiziana ^a   Venturini, Giorgio ^a   Ascenzi, Paolo ^a  

^a ROMA TRE UNIVERSITY   (Italy)

Author keywords

Antiviral agent; Nitric oxide; Virus replication

Indexed keywords

ASPARTIC ACID PROTEINASE; DNA PRIMASE; GLYCOPROTEIN; HELICASE; HEMAGGLUTININ; INTEGRASE; NITRIC OXIDE; NUCLEOCAPSID PROTEIN; PROTEINASE; RIBONUCLEOTIDE REDUCTASE; RNA DIRECTED DNA POLYMERASE; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; VIRUS PROTEIN; ZINC FINGER PROTEIN;

ANTIVIRAL ACTIVITY; DRUG MECHANISM; ENZYME BINDING; ENZYME STRUCTURE; NONHUMAN; OXIDATION REDUCTION REACTION; PROTEIN ISOLATION; REVIEW; TRANSCRIPTION REGULATION; VIRUS CELL INTERACTION;

ANTIVIRAL AGENTS; ASPARTIC ENDOPEPTIDASES; DNA VIRUSES; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; MODELS, MOLECULAR; NITRIC OXIDE; PROTEIN CONFORMATION; RNA VIRUSES; VIRAL PROTEINS;

HERPES; HUMAN HERPESVIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1; RNA VIRUSES;

EID: 0032744568     PISSN: 15216543     EISSN: None     Source Type: Journal    
DOI: 10.1080/152165499307387     Document Type: Review

References (75)

1. Moncada, S., Higgs, A., and Furchgott, R (1997) International Union of Pharmacology nomenclature in nitric oxide research. Pharmacol. Rev. 49, 137-142.
2. Nathan, C. (1992) Nitric oxide as a secretory product of mammalian cells. FASEB J. 6, 3051-3064.
3. Stuehr, D. J. (1997) Structure-function aspects in the nitric oxide synthases. Annu. Rev. Pharmacol. Toxicol. 37, 339-359.
4. Geller, D. A., and Billiar, T. R. (1998) Molecular biology of nitric oxide synthases. Cancer Metastasis Rev. 17, 7-23.
5. Marletta, M. A., Hurshman, A. R., and Rusche, K. M. (1998) Catalysis by nitric oxide synthase. Curr. Opin. Chem. Biol. 2, 656-663.
6. Stamler, J. S. (1994) Redox signaling: nitrosylation and related target interactions of nitric oxide. Cell 78, 931-936.
7. Stamler, J. S. (1995) S-Nitrosothiols and the bioregulalory actions of nitrogen oxides through reactions with thiol groups. Curr. Top. Microbiol. Immunol. 196, 19-36.
8. Stamler, J. S., and Hausladen, A. (1998) Oxidative modifications in nitrosative stress. Nature Struct. Biol. 5, 247-249.
9. Persichini, T., Colasanti, M., Colizzi, V., Fraziano, M., Venturini, G., and Ascenzi, P. (1999) NO and virus. Cell Death Differ. in press.
10. Fields, B. N., Knipe, D. M., Chanock, R. M., Hirsch, M. S., Melnick, J. L., Monath, T. P., and Roizman, B., eds. (1990) Virology, 2nd ed. Raven Press, New York.
11. Barrett, A. J., Rawlings, N. D., and Woessner, J. E, eds. (1998) Handbook of Proteolytic Enzymes. Academic Press, San Diego.
12. Ivanoff, L. A., Towatari, T., Ray, J., Korant, B. D., and Petteway, S. R., Jr. (1986) Expression and site-specific mutagenesis of the poliovirus 3C protease in Escherichia coli. Proc. Natl. Acad. Sci. U.S.A. 83, 5392-5396.
13. Hammerle, T., Hellen, C. U., and Wimmer, E. (1991) Site-directed mutagenesis of the putative catalytic triad of poliovirus 3C proteinase. J. Biol. Chem. 266, 5412-5416.
14. Miyashita, K., Kusumi, M., Utsumi, R., Katayama, S., Noda, M., Komano, T., and Satoh, N. (1993) Site-directed mutagenesis of the putative active site residues of 3C proteinase of coxsackievirus B3: Evidence of a functional relationship with trypsin-like serine proteinases. Protein Eng. 6, 189-193.
15. Saura, M., Zaragoza, C., McMillan, A., Quick, R. A., Hohenadl, C., Lowenstein, J. M., and Lowenstein, C. J. (1999) An antiviral mechanism of nitric oxide: inhibition of a viral protease. Immunity 10, 21-28.
16. Lowenstein, C. J., Hill, S. L., Lafond-Walker, A., Wu, J., Allen, G., Landavere, M., Rose, N. R., and Herskowitz, A. (1996) Nitric oxide inhibits viral replication in murine myocarditis. J. Clin. Invest. 97, 1837-1843.
17. Zaragoza, C., Ocampo, C. J., Saura, M., McMillan, A., and Lowenstein, C. J. (1997) Nitric oxide inhibition of coxsackievirus replication in vitro. J. Clin. Invest. 100, 1760-1767.
18. Zaragoza, C., Ocampo, C., Saura, M., Leppo, M., Wei, X. Q., Quick, R., Moncada, S., Liew, F. Y., and Lowenstein, C. J. (1998) The role of inducible nitric oxide synthase in the host response to coxsackievirus myocarditis. Proc. Natl. Acad. Sci. U.S.A. 95, 2469-2474.
19. Guy, B., Geist, M., Dott, K., Spehner, D., Kieny, M. P., and Lecocq, J. P. (1991) A specific inhibitor of cysteine proteases impairs a vif-dependent modification of human immunodeficiency virus type 1 Env protein. J. Virol. 65, 1325-1331.
20. Ma, X. Y., Sova, P., Chao, W., and Volsky, D. J. (1994) Cysteine residues in the vif protein of human immunodeficiency virus type 1 are essential for viral infectivity. J. Virol. 68, 1714-1720.
21. Frankel, A. D., and Young, J. A. (1993) HIV-1: Fifteen proteins and an RNA. Annu. Rev. Biochem. 67, 1-25.
22. Persichini, T., Colasanti, M., Lauro, G. M., and Ascenzi, P. (1998) Cysteine nitrosylation inactivates the HIV-1 protease. Biochem. Biophys. Res. Commun. 250, 575-576.
23. Hori, K., Burd, P. R., Furuke, K., Kutza, J., Weih, K. A., and Clouse, K. A. (1999) Human immunodeficiency virus-1-infected macrophages induce inducible nitric oxide synthase and nitric oxide (NO) production in astrocytes: astrocytic NO as a possible mediator of neural damage in acquired immunodeficiency syndrome. Blood 93, 1843-1850.
24. Persichini, T., Colasanti, M., Fraziano, M., Colizzi, V., Ascenzi, P., and Lauro, G. M. (1999) Nitric oxide inhibits HIV-1 replication in human astrocytoma cells. Biochem. Biophys. Res. Commun. 254, 200-202.
25. Persichini, T., Colasanti, M., Fraziano, M., Colizzi, V., Medana, C., Polticelli, F., Venturini, G., and Ascenzi, P. (1999) Nitric oxide inhibits the HIV-1 reverse transcriptase activity. Biochem. Biophys. Res. Commun. 258, 624-627.
26. Chavan, S. J., Bornmann, W. G., Flexner, C., and Prochaska, H. J. (1995) Inactivation of human immunodeficiency virus type 1 reverse transcriptase by oltipraz: evidence for the formation of a stable adduct. Arch. Biochem. Biophys. 324, 143-152.
27. Kameoka, M., Okada, Y., Tobiume, M., Kimura, T., and Ikuta, K. (1996) Intracellular glutathione as a possible direct blocker of HIV type 1 reverse transcription. AIDS Res. Hum. Retroviruses 12, 1635-1638.
28. Loya, S., Gao, H. Q., Avidan, O., Boyer, P. L., Hughes, S. H., and Hizi, A. (1997) Subunit-specific mutagenesis of the cysteine 280 residue of the reverse transcriptase of human immunodeficiency virus type 1: Effects on sensitivity to a specific inhibitor of the RNase H activity. J. Virol. 71, 5668-5672.
29. Lepoivre, M., Fieschi, F., Coves, J., Thelander, L., and Fontecave, M. (1991) Inactivation of ribonucleotide reductase by nitric oxide. Biochem. Biophys. Res. Commun. 179, 442-448.
30. Karupiah, G., Xie, Q.-W., Buller, R. M. L., Nathan, C., Duarte, C., and MacMicking, J. D. (1993) Inihibition of viral replication by interferon-γ-induced nitric oxide synthase. Science 261, 1445-1448.
31. Karupiah, G., and Harris, N. (1995) Inhibition of viral replication by nitric oxide and its reversal by ferrous sulphate and tricarboxylic acid cycle metabolites. J. Exp. Med. 181, 2171-2179.
32. Harris, N., Buller, R. M., and Karupiah, G. (1995) Gamma interferon-induced, nitric oxide-mediated inhibition of vaccinia virus replication. J. Virol. 69, 910-915.
33. Mannick, J. B. (1995) The antiviral role of nitric oxide. Res. Immunol. 146, 693-697.
34. Olcott, M. C., Andersson, J., and Sjoberg, B. M. (1998) Localization and characterization of two nucleotide-binding sites on the anaerobic ribonucleotide reductase from bacteriophage T4. J. Biol. Chem. 273, 24853-24860.
35. Chevallier-Greco, A., Manet, E., Chavrier, P., Mosnier, C., Daillie, J., and Sergeant, A. (1986) Both Epstein-Barr virus (EBV)-encoded trans-acting factors, EB1 and EB2, are required to activate transcription from an EBV early promoter. EMBO J. 5, 3243-3249.
36. Abate, C., Patel, L., Rauscher, F. J. III, and Curran, T. (1990) Redox regulation of fos and jun DNA-binding activity in vitro. Science 249, 1157-1161.
37. Flemington, E., and Speck, S. H. (1990) Autoregulation of Epstein-Barr virus putative lytic switch gene BZLF1. J. Virol. 64, 1227-1232.
38. Bannister, A. J., Cook, A., and Kouzarides, T. (1991) In vitro DNA binding activity of Fos/Jun and BZLF1 but not C/EBP is affected by redox changes. Oncogene 6, 1243-1250.
39. Mannick, J. B., Asano, K., Izumi, K., Kieff, E., and Stamler, J. S. (1994) Nitric oxide produced by human B lymphocytes inhibits apoptosis and Epstein-Barr virus reactivation. Cell 79, 1137-1146.
40. Landschulz, W. H., Johnson, P. F., and McKnight, S. L. (1988) The leucine zipper: a hypothetical structure common to a new class of DNA binding proteins. Science 240, 1759-1764.
41. Farrell, P. J., Rowe, D. T., Rooney, C. M., and Kouzarides, T. (1989) Epstein-Barr virus BZLF1 trans-activator specifically binds to a consensus AP-1 site and is related to c-fos. EMBO J. 8, 127-132.
42. Vaishnav, Y. N., and Wong-Staal, F. (1991) The biochemistry of AIDS. Annu. Rev. Biochem. 60, 577-630.
43. Matthews, J. R., Botting, C. H., Panico, M., Morris, H. R., and Hay, R. T. (1996) Inhibition of NF-kappaB DNA binding by nitric oxide. Nucleic Acid. Res. 24, 2236-2242.
44. Sekkai, D., Aillet, F., Israel, N., and Lepoivre, M. (1998) Inhibition of NF-κB and HIV-1 long terminal repeat transcriptional activation by inducible nitric oxide synthase 2 activity. J. Biol. Chem. 273, 3895-3900.
45. Kubota, S., Endo, S., Maki, M., and Hatanaka, M. (1989) A region of basic amino-acid cluster in HIV-1 Tat protein is essential for trans-acting activity and nucleolar localization. Virus Genes 2, 113-118.
46. Sadaie, M. R., Mukhopadhyaya, R., Benaissa, Z. N., Pavlakis, G. N., and Wong-Staal, F. (1990) Conservative mutations in the putative metal-binding region of human immunodeficiency virus tat disrupt virus replication. AIDS Res. Hum. Retroviruses 6, 1257-1263.
47. Balboni, P. G., Bozzini, R., Zucchini, S., Marconi, P. C., Grossi, M. P., Caputo, A., Manservigi, R., and Barbanti-Brodano, G. (1993) Inhibition of human immunodeficiency virus reactivation from latency by a tat transdominant negative mutant. J. Med. Virol. 41, 289-295.
48. Shoji, S., Furuishi, K., Misumi, S., Miyazaki, T., Kino, M., and Yamataka, K. (1994) Thiamine disulfide as a potent inhibitor of human immunodeficiency virus (type-1) production. Biochem. Biophys. Res. Commun. 205, 967-975.
49. Bushman, F. D., Engelman, A., Palmer, I., Wingfield, P., and Craigie, R. (1993) Domains of the integrase protein of human immunodeficiency virus type 1 responsible for polynucleotidyl transfer and zinc binding. Proc. Natl. Acad. Sci. U.S.A. 90, 3428-3432.
50. Vincent, K. A., Ellison, V., Chow, S. A., and Brown, P. O. (1993) Characterization of human immunodeficiency virus type 1 integrase expressed in Escherichia coli and analysis of variants with amino-terminal mutations. J. Virol. 67, 425-437.
51. Eijkelenboom, A. P., van den Ent, F. M., Vos, A., Doreleijers, J. F., Hard, K., Tullius, T. D., Plasterk, R. H., Kaptein, R., and Boelens, R. (1997) The solution structure of the amino-terminal HHCC domain of HIV-2 integrase: A three-helix bundle stabilized by zinc. Curr. Biol. 7, 739-746.
52. 2+ finger motif of UL52 severely affects the biochemical activities of the HSV-1 helicase-primase subcomplex. J. Biol. Chem. 274, 8068-8076.
53. Croen, K. D. (1993) Evidence for antiviral effect of nitric oxide. Inhibition of herpes simplex virus type 1 replication. J. Clin. Invest. 91, 2446-2452.
54. Komatsu, T., Bi, Z., and Reiss, C. S. (1996) Interferon-gamma induced type I nitric oxide synthase activity inhibits viral replication in neurons. J. Neuroimmunol. 68, 101-108.
55. Ott, D. E., Hewes, S. M., Alvord, W. G., Henderson, L. E., and Arthur, L. O. (1998) Inhibition of Friend virus replication by a compound that reacts with the nucleocapsid zinc finger: Anti-retroviral effect demonstrated in vivo. Virology 243, 283-292.
56. Akarid, K., Sinet, M., Desforges, B., and Gougerot-Pocidalo, M. A. (1995) Inhibitory effect of nitric oxide on the replication of a murine retrovirus in vitro and in vivo. J. Virol. 69, 7001-7005.
57. Huang, M., Maynard, A., Turpin, J. A., Graham, L., Janini, G. M., Covell, D. G., and Rice, W. G. (1998) Anti-HIV agents that selectively target retroviral nucleocapsid protein zinc fingers without affecting cellular zinc finger proteins. J. Med. Chem. 41, 1371-1381.
58. Schiff, L. A., Nibert, M. L., Co, M. S., Brown, E. G., and Fields, B. N. (1988) Distinct binding sites for zinc and double-stranded RNA in the reovirus outer capsid protein sigma 3. Mol. Cell. Biol. 8, 273-283.
59. Lee, M. S., Mortishire-Smith, R. J., and Wright, P. E. (1992) The zinc-finger motif: conservation of chemical shifts and correlation with structure. FEBS Lett. 31, 29-32.
60. Pertile, T. L., Karaca, K., Sharma, J. M., and Walser, M. M. (1996) An antiviral effect of nitric oxide: Inhibition of reovirus replication. Avian Dis. 40, 342-248.
61. Rose, J. K., Adams, G. A., and Gallione, C. J. (1984) The presence of cysteine in the cytoplasmic domain of the vesicular stomatitis virus glycoprotein is required for palmitate addition. Proc. Natl. Acad. Sci. U.S.A. 81, 2050-2054.
62. Scullion, B. F., Hou, Y., Puddington, L., Rose, J. K., and Jacobson, K. (1987) Effects of mutations in three domains of the vesicular stomatitis viral glycoprotein on its lateral diffusion in the plasma membrane. J. Cell. Biol. 105, 69-75; erratum appears in (1988) J. Cell Biol. 106, 325.
63. Mack, D., and Kruppa, J. (1988) Fatty acid acylation at the single cysteine residue in the cytoplasmic domain of the glycoprotein of vesicular-stomatitis virus. Biochem. J. 256, 1021-1027.
64. Coll, J. M. (1995) The glycoprotein G of rhabdoviruses. Arch. Virol. 140, 827-851.
65. Laquerre, S., Anderson, D. B., Argnani, R., and Glorioso, J. C. (1998) Herpes simplex virus type I glycoprotein B requires a cysteine residue at position 633 for folding, processing, and incorporation into mature infectious virus particles. J. Virol. 72, 4940-4949.
66. Eickmann, M., Lange, R., Ohlin, M., Reschke, M., and Radsak, K. (1998) Effect of cysteine substitutions on dimerization and interfragment linkage of human cytomegalovirus glycoprotein B (gp UL55). Arch. Virol. 143, 1865-1880.
67. Fischer, C., Schroth-Diez, B., Herrmann, A., Garten, W., and Klenk, H. D. (1998) Acylation of the influenza hemagglutinin modulates fusion activity. Virology 248, 284-294.
68. Powell, K. L., and Baylis, S. A. (1995) The antiviral effects of nitric oxide. Trends Microbiol. 3, 81-82.
69. Peterhans, E. (1997) Reactive oxygen species and nitric oxide in viral diseases. Biol. Trace Elem. Res. 56, 107-116.
70. Maeda, H., and Akaike, T. (1998) Nitric oxide and oxygen radicals in infection, inflammation, and cancer. Biochemistry (Mosc.) 63, 854-865.
71. Reiss, C. S., and Komatsu, T. (1998) Does nitric oxide play a critical role in viral infections? J. Virol. 72, 4547-4551.
72. Stamler, J. S., Simon, D. I., Osborne, J. A., Mullins, M. E., Jaraki, O., Michel, T., Singel, D. J., and Loscalzo, J. (1992) S-Nitrosylation of proteins with nitric oxide: synthesis and characterization of biologically active compounds. Proc. Natl. Acad. Sci. U.S.A. 89, 444-448.
73. Banki, K., Hutter, E., Gonchoroff, N. J., and Perl, A. (1998) Molecular ordering in HIV-induced apoplosis: Oxidative stress, activation of caspases, and cell survival are regulated by transaldolase. J. Biol. Chem. 273, 11944-11953.
74. Martindale, J. (1996) The Extra Pharmacopoeia, 31st ed. (James, E., and Reynolds, F., eds.). The Pharmaceutical Press, London.
75. Koradi, R., Billeter, M., and Wüthrich, K. (1996) MOLMOL: a program for display and analysis of macromolecular structures. J. Mol. Graphics 14, 51-55.